Prevalence and Recovery From Olfactory and Gustatory Dysfunctions in Covid-19 Infection: A Prospective Multicenter Study.
Adult
Aged
Aged, 80 and over
Betacoronavirus
COVID-19
Coronavirus Infections
/ complications
Female
Follow-Up Studies
France
/ epidemiology
Humans
Male
Middle Aged
Olfaction Disorders
/ etiology
Olfactory Perception
/ physiology
Pandemics
Pneumonia, Viral
/ complications
Prevalence
Prospective Studies
Recovery of Function
SARS-CoV-2
Taste Disorders
/ epidemiology
Taste Perception
/ physiology
Young Adult
Ageusia
Anosmia
Covid-19
Gustatory disorders
Olfactory disorders
Recovery
SARS-CoV-2
Journal
American journal of rhinology & allergy
ISSN: 1945-8932
Titre abrégé: Am J Rhinol Allergy
Pays: United States
ID NLM: 101490775
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
13
6
2020
medline:
22
8
2020
entrez:
13
6
2020
Statut:
ppublish
Résumé
Covid-19 is defined by an association of multiple symptoms, including frequently reported olfactory and gustatory disorders. The main purpose of this study was to analyze the prevalence of these neurosensory impairments in patients with Covid-19, and to assess short-term recovery. We performed a multicenter case series study during the Covid-19 epidemic. All patients presenting a RT-PCR-confirmed SARS-CoV-2 infection were included, whether hospitalized or treated at home. To analyze the prevalence and features of olfactory and gustatory dysfunctions, a phone interview was conducted 5 days after the positive PCR result. The questionnaire was submitted again 10 days later to patients having reported olfactory and gustatory disorders, in order to assess their recovery. 115 patients were included in our study. 81 patients (70%) reported olfactory and gustatory disorders without nasal obstruction or rhinorrhea. These impairments were more frequently reported in the female population, young people, and house-bound patients with mild symptomatic forms. Short-term recovery assessed at Day 15 was complete for 64% of the patients, and incomplete in 33%. Median recovery time was 15 days (4-27 days) after olfactory or gustatory symptom onset. Olfactory and gustatory dysfunctions related to Covid-19 are frequently reported and prevalent in mild symptomatic forms of the disease. Recovery in most cases seems rapid and complete.
Sections du résumé
BACKGROUND
BACKGROUND
Covid-19 is defined by an association of multiple symptoms, including frequently reported olfactory and gustatory disorders.
OBJECTIVE
OBJECTIVE
The main purpose of this study was to analyze the prevalence of these neurosensory impairments in patients with Covid-19, and to assess short-term recovery.
METHODS
METHODS
We performed a multicenter case series study during the Covid-19 epidemic. All patients presenting a RT-PCR-confirmed SARS-CoV-2 infection were included, whether hospitalized or treated at home. To analyze the prevalence and features of olfactory and gustatory dysfunctions, a phone interview was conducted 5 days after the positive PCR result. The questionnaire was submitted again 10 days later to patients having reported olfactory and gustatory disorders, in order to assess their recovery.
RESULTS
RESULTS
115 patients were included in our study. 81 patients (70%) reported olfactory and gustatory disorders without nasal obstruction or rhinorrhea. These impairments were more frequently reported in the female population, young people, and house-bound patients with mild symptomatic forms. Short-term recovery assessed at Day 15 was complete for 64% of the patients, and incomplete in 33%. Median recovery time was 15 days (4-27 days) after olfactory or gustatory symptom onset.
CONCLUSION
CONCLUSIONS
Olfactory and gustatory dysfunctions related to Covid-19 are frequently reported and prevalent in mild symptomatic forms of the disease. Recovery in most cases seems rapid and complete.
Identifiants
pubmed: 32527141
doi: 10.1177/1945892420930954
pmc: PMC7418272
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
686-693Références
Lab Anim Sci. 1990 Sep;40(5):481-5
pubmed: 2170746
Am J Otolaryngol. 2020 May - Jun;41(3):102474
pubmed: 32278470
J Neurol Sci. 2020 May 15;412:116824
pubmed: 32299010
EMBO J. 2005 Apr 20;24(8):1634-43
pubmed: 15791205
Maxillofac Plast Reconstr Surg. 2020 Mar 30;42(1):9
pubmed: 32289035
Laryngoscope. 2014 Apr;124(4):826-31
pubmed: 23929687
Int Forum Allergy Rhinol. 2020 Jul;10(7):806-813
pubmed: 32279441
Arch Otolaryngol Head Neck Surg. 2002 Jun;128(6):635-41
pubmed: 12049556
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Eur Arch Otorhinolaryngol. 2012 Jan;269(1):143-53
pubmed: 21739093
Cell Discov. 2020 Feb 24;6:11
pubmed: 32133153
J Virol. 2008 Aug;82(15):7264-75
pubmed: 18495771
Eur Arch Otorhinolaryngol. 2007 Mar;264(3):237-43
pubmed: 17021776
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Front Immunol. 2019 May 09;10:1052
pubmed: 31143188
Rhinology. 2020 Jun 1;58(3):295-298
pubmed: 32277751
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
Otolaryngol Head Neck Surg. 2020 Jul;163(1):132-134
pubmed: 32340555
Arch Otolaryngol Head Neck Surg. 2004 Mar;130(3):317-9
pubmed: 15023839
Int J Antimicrob Agents. 2020 May;55(5):105955
pubmed: 32234468
Chem Senses. 2017 Sep 1;42(7):513-523
pubmed: 28531300
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143